摘要
背景:大量研究表明,在心脏手术的围手术期给药时,卤化药物会引起心肌调理作用。最近发表的证据表明在术后早期保持暴露于卤化剂的益处。最近解释了发挥这种有益作用的酶促机制。目的:我们的研究旨在调查这种现象是否由卤化麻醉剂靶向的 miRNA 的激活或抑制介导。 方法:进行了一项双盲、两阶段试验。本文介绍了第一阶段试验的结果。样本由接受非体外循环心肌血运重建手术的患者组成。在术中和术后早期(干预后的前六小时),患者被随机分配接受七氟醚 [S] 或丙泊酚 [P]。在前 48 小时内每隔 6 小时监测血流动力学(心率、血压、中心静脉压、心脏指数、收缩容积指数、LVEF)和心肌酶(肌钙蛋白 I)。在试验的第一阶段,在基线和 24 小时从八名患者(每组四名)抽取血液进行基因测序。在研究的第二阶段,对通过基因测序确定为显着的 miRNA 进行 qPCR 分析。测量心脏保护酶(丝氨酸/苏氨酸蛋白激酶(Akt)、肿瘤坏死因子α(TNFα)、细胞外调节蛋白激酶(ERK 1/2)和半胱天冬酶3)的水平以评估它们在心肌调理途径中的作用。目的是确定在卤化剂诱导的心肌调理中起主要作用的 miRNA。服用七氟醚的患者心脏保护酶的浓度高于服用丙泊酚的患者。 结果:在两个研究组的基线值和 24 小时值之间观察到 NGS 差异。在P组中,miRNA 197-3p过度表达,而miRNA 4443和1294、708-3p表达不足。 S组中,miRNAs 615-3p、4466、29、937-3p、636、197-3P、184、4685、296-3p、147b、3199、6815、1294和3176表达不足;而 708-3p 被过度表达。 qPCR 显示 P 组中 miRNA 197-3p、4443、708-3p 和 1294 以及 S 组中 miRNA 937-3p、636、197-3p、296-3p 和 708-3p 的显着变异。 结论:在 P 组中,一些 miRNA 表达的变化与较低浓度的参与心肌预处理和后处理的酶有关。相比之下,在 S 组中,miRNA 的变异与麻醉剂诱导的预处理和后处理介质的激活、细胞凋亡的减少以及 caspase 和 TnBF α 浓度的降低有关。这些 miRNA 的变化与缺血性心脏病患者的更好预后相关。这项研究的主要局限性将在试验的第二阶段得到克服,届时将确定每个 miRNA 的具体作用。
关键词: miRNAs,心脏麻醉,预处理,后处理,aconditioning,卤化。
Current Medicinal Chemistry
Title:NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Volume: 28 Issue: 20
关键词: miRNAs,心脏麻醉,预处理,后处理,aconditioning,卤化。
摘要:
Background: Numerous studies have demonstrated that halogenated agents elicit myocardial conditioning effects when administered perioperatively in cardiac surgery. Recent evidence has been published on the benefits of maintaining exposure to halogenated agents during the early postoperative period. The enzymatic mechanisms by which this beneficial effect is exerted were explained recently.
Objectives: Our study was performed to investigate whether this phenomenon is mediated by either the activation or suppression of miRNAs targeted by halogenated anesthetics.
Methods: A double-blind, two-stage trial was conducted. The results of the first stage of the trial are presented in this paper. The sample was composed of patients undergoing off-pump myocardial revascularization surgery. Patients were randomized to receive either sevoflurane [S] or propofol [P] during the intraoperative and early postoperative period (during the first six hours after the intervention). Hemodynamics (heart rate, blood pressure, central venous pressure, cardiac index, systolic volume index, LVEF) and myocardial enzymes (troponin I) were monitored at six hour intervals during the first 48 hours. In the first stage of the trial, blood was drawn for gene sequencing from eight patients (four per group) at baseline and at 24 h. In the second stage of the study, a qPCR analysis was performed of the miRNAs identified as significant by gene sequencing. Levels of cardioprotective enzymes (serine/threonine protein kinase (Akt), tumor necrosis factor alpha (TNFα), extracellular regulated protein kinase (ERK 1/2), and caspase 3) were measured to assess their role in myocardial conditioning pathways. The purpose was to identify the miRNAs that play a major role in myocardial conditioning induced by halogenated agents. Concentrations of cardioprotective enzymes were higher in patients who received sevoflurane than the patients who were administered propofol.
Results: NGS differences were observed between baseline and 24-h values in the two study groups. In group P, miRNA 197-3p was overexpressed, whereas miRNAs 4443 and 1294, 708-3p were underexpressed. In group S, miRNAs 615-3p, 4466, 29, 937-3p, 636, 197-3P, 184, 4685, 296-3p, 147b, 3199, 6815, 1294 and 3176 were underexpressed; whereas 708-3p was overexpressed. qPCR showed significant variations in miRNAs 197-3p, 4443, 708-3p and 1294 in the P group, and in miRNAs 937-3p, 636, 197- 3p, 296-3p and 708-3p in the S group.
Conclusion: In the P Group, changes in the expression of some miRNAs were associated with lower concentrations of the enzymes involved in myocardial pre- and postconditioning. In contrast, in Group S, variations in miRNAs were associated with the activation of mediators of anesthetic-induced pre- and post-conditioning, a reduction in cell apoptosis, and a decrease in caspase and TnBF alpha concentrations. Changes in these miRNAs were associated with better prognosis in patients with ischemic heart disease. The main limitation of this study will be overcome in the second stage of the trial, where the specific role of each miRNA will be determined.
Export Options
About this article
Cite this article as:
NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial, Current Medicinal Chemistry 2021; 28 (20) . https://dx.doi.org/10.2174/0929867327999201001202607
DOI https://dx.doi.org/10.2174/0929867327999201001202607 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Engineering in Allotransplantation of Vascularized Organs
Current Gene Therapy Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Renal-Protective Activity of Dried Gel of <i>Aloe barbadensis</i> (Elwa) on Gentamicin- Induced Nephrotoxicity in Albino Rats
Current Traditional Medicine Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors
Current Neurovascular Research Inflammatory Mechanisms in Myocardial Infarction
Current Drug Targets - Inflammation & Allergy Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology A Path to Development or Demise ?
Current Neurovascular Research Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Urocortins: Putative Role in Cardiovascular Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pharmacological Pre- and Post- Conditioning Agents: Reperfusion-Injury of the Heart Revisited
Mini-Reviews in Medicinal Chemistry Intracranial Aneurysms in Sickle Cell Disease
Current Neurovascular Research Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Curcumin and Endothelial Function: Evidence and Mechanisms of Protective Effects
Current Pharmaceutical Design Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades
Current Pharmaceutical Design Animal Models of Focal Cerebral Ischaemia and Haemorrhagic Transformation: Considerations in Experimental Stroke Study Design
Current Vascular Pharmacology